New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism

[1]  S. Garg,et al.  Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy , 2019, JAMA ophthalmology.

[2]  Jian-xing Ma,et al.  Neuroprotective effects of PPARα in retinopathy of type 1 diabetes , 2019, PloS one.

[3]  W. L. Beeson,et al.  Effects of omega-3 polyunsaturated fatty-acid supplementation on neuropathic pain symptoms and sphingosine levels in Mexican-Americans with type 2 diabetes , 2019, Diabetes, metabolic syndrome and obesity : targets and therapy.

[4]  Jian-xing Ma,et al.  Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress–mediated Wnt/β-catenin pathway activation , 2019, Cell and Tissue Research.

[5]  Brett A. McGregor,et al.  Conserved Transcriptional Signatures in Human and Murine Diabetic Peripheral Neuropathy , 2018, Scientific Reports.

[6]  A. Bookout,et al.  Liver X Receptors Protect Dorsal Root Ganglia from Obesity-Induced Endoplasmic Reticulum Stress and Mechanical Allodynia , 2018, Cell reports.

[7]  Yue Zhou,et al.  Relationship between dyslipidemia and diabetic retinopathy , 2018, Medicine.

[8]  M. Yorek.  The Potential Role of Fatty Acids in Treating Diabetic Neuropathy , 2018, Current Diabetes Reports.

[9]  Zhi Zheng,et al.  Fenofibrate Exerts Protective Effects in Diabetic Retinopathy via Inhibition of the ANGPTL3 Pathway. , 2018, Investigative ophthalmology & visual science.

[10]  J. Hur,et al.  Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story , 2018, Experimental Neurology.

[11]  M. Cooper,et al.  Cardiovascular Disease and Diabetic Kidney Disease. , 2018, Seminars in nephrology.

[12]  P. Fort,et al.  Role of Inflammation in Diabetic Retinopathy , 2018, International journal of molecular sciences.

[13]  G. Michailidis,et al.  Lipidomics and Biomarker Discovery in Kidney Disease. , 2018, Seminars in nephrology.

[14]  M. Banerjee,et al.  Diabetes and obesity are the main metabolic drivers of peripheral neuropathy , 2018, Annals of clinical and translational neurology.

[15]  W. Hauswirth,et al.  ELOVL4-Mediated Production of Very Long-Chain Ceramides Stabilizes Tight Junctions and Prevents Diabetes-Induced Retinal Vascular Permeability , 2018, Diabetes.

[16]  Shenmin Zhang,et al.  Retinal de novo lipogenesis coordinates neurotrophic signaling to maintain vision , 2018, JCI insight.

[17]  E. Feldman,et al.  Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  E. Gratton,et al.  FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. , 2017, Journal of the American Society of Nephrology : JASN.

[19]  Subramaniam Pennathur,et al.  Impaired β-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[20]  P. Rossing,et al.  Diagnosis of diabetic kidney disease: state of the art and future perspective. , 2018, Kidney international supplements.

[21]  M. Levi,et al.  Bile acid receptors and the kidney , 2018, Current opinion in nephrology and hypertension.

[22]  Jian-xing Ma,et al.  Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation , 2018, Molecular and Cellular Biochemistry.

[23]  H. V. Jagadish,et al.  Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model[S] , 2017, Journal of Lipid Research.

[24]  Olov Rolandsson,et al.  Screening for type 2 diabetes: do screen-detected cases fare better? , 2017, Diabetologia.

[25]  Jennifer K. Sun,et al.  Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. , 2017, JCI insight.

[26]  G. Malek,et al.  The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor , 2017, EBioMedicine.

[27]  Lois E. H. Smith,et al.  ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases. , 2017, The American journal of clinical nutrition.

[28]  T. Wolever,et al.  Effect of omega-3 supplementation on neuropathy in type 1 diabetes , 2017, Neurology.

[29]  M. Woodward,et al.  Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. , 2017, The lancet. Diabetes & endocrinology.

[30]  L. Feldman,et al.  Mitochondria Protection after Acute Ischemia Prevents Prolonged Upregulation of IL-1β and IL-18 and Arrests CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[31]  S. Saydah,et al.  Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012 , 2017, The New England journal of medicine.

[32]  K. Nave,et al.  New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain , 2017, Neuron.

[33]  Felix Eichinger,et al.  Comparative RNA‐Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease , 2017, Journal of cellular and molecular medicine.

[34]  T. Becker,et al.  Effects of lipids on mitochondrial functions. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[35]  Jian-xing Ma,et al.  Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma. , 2016, Experimental eye research.

[36]  R. Lamuela-Raventós,et al.  Dietary Marine ω-3 Fatty Acids and Incident Sight-Threatening Retinopathy in Middle-Aged and Older Individuals With Type 2 Diabetes: Prospective Investigation From the PREDIMED Trial. , 2016, JAMA ophthalmology.

[37]  Kumar Sharma,et al.  Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. , 2016, JCI insight.

[38]  Jiang He,et al.  Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort , 2016, Kidney international reports.

[39]  K. Sharma,et al.  Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer , 2016, American Journal of Nephrology.

[40]  E. Kang,et al.  Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia , 2016, PloS one.

[41]  P. Reddy,et al.  Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease. , 2016, Human molecular genetics.

[42]  M. Banerjee,et al.  Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status , 2016, Diabetes Care.

[43]  Marin L. Gantner,et al.  Retinal lipid and glucose metabolism dictates angiogenesis through lipid sensor Ffar1 , 2016, Nature Medicine.

[44]  Mitsuo Kato,et al.  Epigenetic Histone Modifications Involved in Profibrotic Gene Regulation by 12/15-Lipoxygenase and Its Oxidized Lipid Products in Diabetic Nephropathy. , 2016, Antioxidants & redox signaling.

[45]  Jessica Pham,et al.  Metabolomics Reveals a Key Role for Fumarate in Mediating the Effects of NADPH Oxidase 4 in Diabetic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[46]  E. Feldman,et al.  Distal Symmetric Polyneuropathy: A Review. , 2015, JAMA.

[47]  Lei Zhang,et al.  Dietary fish oil inhibits mechanical allodynia and thermal hyperalgesia in diabetic rats by blocking nuclear factor-κB-mediated inflammatory pathways. , 2015, The Journal of nutritional biochemistry.

[48]  R. Petersen,et al.  Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental Diabetic Neuropathy , 2015, Diabetes.

[49]  S. Sivaprasad,et al.  Cross Talk between Lipid Metabolism and Inflammatory Markers in Patients with Diabetic Retinopathy , 2015, Journal of diabetes research.

[50]  Glen T. Prusky,et al.  A mitochondrial therapeutic reverses visual decline in mouse models of diabetes , 2015, Disease Models & Mechanisms.

[51]  V. Nair,et al.  Targeted Lipidomic and Transcriptomic Analysis Identifies Dysregulated Renal Ceramide Metabolism in a Mouse Model of Diabetic Kidney Disease , 2015, Journal of proteomics & bioinformatics.

[52]  Chelsea E. Myers,et al.  Serum Lipids and Proliferative Diabetic Retinopathy and Macular Edema in Persons With Long-term Type 1 Diabetes Mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. , 2015, JAMA ophthalmology.

[53]  J. Mann,et al.  Pathways of polyunsaturated fatty acid utilization: Implications for brain function in neuropsychiatric health and disease , 2015, Brain Research.

[54]  Kumar Sharma,et al.  Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development , 2014, Nature Medicine.

[55]  A. Keech,et al.  Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina. , 2014, The American journal of pathology.

[56]  E. Feldman,et al.  Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction. , 2014, Antioxidants & redox signaling.

[57]  Han-Kyu Lee,et al.  Oleate prevents palmitate-induced mitochondrial dysfunction, insulin resistance and inflammatory signaling in neuronal cells. , 2014, Biochimica et biophysica acta.

[58]  M. Boulton,et al.  Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes1 , 2014, Journal of Lipid Research.

[59]  T. Gardner,et al.  Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment , 2014, Annals of the New York Academy of Sciences.

[60]  A. Tobar,et al.  Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy , 2014, Journal of Lipid Research.

[61]  Cheng Wang,et al.  Simvastatin Alleviates Hyperpermeability of Glomerular Endothelial Cells in Early-Stage Diabetic Nephropathy by Inhibition of RhoA/ROCK1 , 2013, PloS one.

[62]  J. Singleton,et al.  Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. , 2013, Journal of diabetes and its complications.

[63]  J. Milbrandt,et al.  Aberrant Schwann Cell Lipid Metabolism Linked to Mitochondrial Deficits Leads to Axon Degeneration and Neuropathy , 2013, Neuron.

[64]  C. Tseng,et al.  Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. , 2013, The review of diabetic studies : RDS.

[65]  M. Cooper,et al.  Mechanisms of diabetic complications. , 2013, Physiological reviews.

[66]  F. Vaz,et al.  Acylcarnitines , 2012, Diabetes.

[67]  R. Hamman,et al.  Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050 , 2012, Diabetes Care.

[68]  R. Hughes,et al.  ENHANCED GLUCOSE CONTROL FOR PREVENTING AND TREATING DIABETIC NEUROPATHY , 2012, The Cochrane database of systematic reviews.

[69]  K. Martin,et al.  Aldose Reductase, Oxidative Stress, and Diabetic Mellitus , 2012, Front. Pharmacol..

[70]  Jean-Pierre A. Kocher,et al.  Concordance of Changes in Metabolic Pathways Based on Plasma Metabolomics and Skeletal Muscle Transcriptomics in Type 1 Diabetes , 2012, Diabetes.

[71]  B. Klein,et al.  Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.

[72]  G. Cavaletti,et al.  Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation[S] , 2012, Journal of Lipid Research.

[73]  P. Reaven,et al.  Does Aggressive Glycemic Control Benefit Macrovascular and Microvascular Disease in Type 2 Diabetes?: Insights from ACCORD, ADVANCE, and VADT , 2012, Current Cardiology Reports.

[74]  H. V. Jagadish,et al.  The identification of gene expression profiles associated with progression of human diabetic neuropathy. , 2011, Brain : a journal of neurology.

[75]  P. Fort,et al.  Differential Roles of Hyperglycemia and Hypoinsulinemia in Diabetes Induced Retinal Cell Death: Evidence for Retinal Insulin Resistance , 2011, PloS one.

[76]  M. Kretzler,et al.  Transcriptional Profiling of Diabetic Neuropathy in the BKS db/db Mouse , 2011, Diabetes.

[77]  H. Szeto,et al.  Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. , 2011, Journal of the American Society of Nephrology : JASN.

[78]  K. Lanoue,et al.  The influence of diabetes on glutamate metabolism in retinas , 2011, Journal of neurochemistry.

[79]  S. Carr,et al.  Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. , 2011, The Journal of clinical investigation.

[80]  V. Gebski,et al.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study , 2011, Diabetologia.

[81]  D. Choudhury,et al.  Diabetic nephropathy -- a multifaceted target of new therapies. , 2010, Discovery medicine.

[82]  Ferdinando Giacco,et al.  Oxidative stress and diabetic complications. , 2010, Circulation research.

[83]  Merlin C. Thomas,et al.  The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. , 2010, American journal of physiology. Renal physiology.

[84]  Walter T Ambrosius,et al.  Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.

[85]  G. Hitman,et al.  Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[86]  G. Reid,et al.  Remodeling of Retinal Fatty Acids in an Animal Model of Diabetes , 2009, Diabetes.

[87]  E. Feldman,et al.  Dyslipidemia-Induced Neuropathy in Mice , 2009, Diabetes.

[88]  M. Laakso,et al.  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial , 2009, The Lancet.

[89]  E. Feldman,et al.  Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy , 2009, Diabetes.

[90]  R. Holle,et al.  Subclinical Inflammation and Diabetic Polyneuropathy , 2009, Diabetes Care.

[91]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[92]  E. Feldman,et al.  Dyslipidemia-Induced Neuropathy in Mice : the Role of oxLDL / LOX-1 , 2009 .

[93]  B. Davis,et al.  Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[94]  G. Bakris,et al.  The pathogenesis of diabetic nephropathy , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[95]  P. Mitchell,et al.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[96]  Lois E. H. Smith,et al.  Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.

[97]  Juan Fernández,et al.  Renal and retinal microangiopathy after 15 years of follow-up study in a sample of Type 1 diabetes mellitus patients. , 2007, Journal of diabetes and its complications.

[98]  G. Sparagna,et al.  Role of cardiolipin alterations in mitochondrial dysfunction and disease. , 2007, American journal of physiology. Cell physiology.

[99]  M. Tonelli,et al.  Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.

[100]  M. Taskinen,et al.  Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[101]  Y. Guan.  Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. , 2004, Journal of the American Society of Nephrology : JASN.

[102]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[103]  Jinhai Gao,et al.  Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors , 2004, Nature.

[104]  Vishali Gupta,et al.  Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. , 2004, American journal of ophthalmology.

[105]  O. Pedersen,et al.  [The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]. , 2003, Ugeskrift for laeger.

[106]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[107]  R. Pandey,et al.  Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. , 2002, Diabetes research and clinical practice.

[108]  I. Goldberg.  Diabetic Dyslipidemia: Causes and Consequences , 2001 .

[109]  R. Donnelly,et al.  The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. , 1999, British journal of clinical pharmacology.

[110]  H. Dorchy,et al.  Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. , 1998, Atherosclerosis.

[111]  P. Dyck,et al.  Pathologic Alterations in the Diabetic Neuropathies of Humans: A Review , 1996, Journal of neuropathology and experimental neurology.

[112]  B. Hoogwerf,et al.  Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. , 1996, Archives of ophthalmology.

[113]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[114]  A. Avogaro,et al.  Metabolic Control of Kidney Hemodynamics in Normal and Insulin-Dependent Diabetic Subjects: Effects of Acetoacetic, Lactic, and Acetic Acids , 1987, Diabetes.